Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) today announced that the 505(b)(2) New Drug Application (NDA) for its novel pemetrexed drug product ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE